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The in vitro effect of thymosin fraction 5, a thymic gland extract, on thymus-dependent 
lymphocytes was studied in 12 patients with alcoholic hepatitis (AH) and in 18 patients 
with compensated alcoholic cirrhosis (CAC). The baseline number and proportion of 
spontaneous rosette-forming T lymphocytes were significantly reduced in AH as com- 
pared to the controls. No such decrease was seen in CAC. When the lymphocytes of 
patients with AH were incubated in the presence of thymosin fraction 5, the subsequent 
number and proportion of rosette-forming T lymphocytes showed a significant increase. 
There was no significant reponse to thymosin in CAC or in control subjects. There 
appears to be a subset of immature T lymphocytes in patients with AH that is responsive 
to exogenous thymic factors with subsequent activation of the capacity to form spon- 
taneous rosettes. 
INTRODUCTION 
Identification and enumeration of peripheral T and B lymphocytes in patients 
with alcoholic liver disease has resulted in reports of diminished numbers of T but 
not B cells (l-8). Additional alterations in cell-mediated immunity (1, 5) suggest 
the possibility of a dysfunction in the regulatory role for the endocrine thymus in 
the ontogenesis and function of the T-lymphoid system. 
Thymosin, a polypeptide extract of calf thymus, has been shown, in vifro, to 
increase the percentage of spontaneous T-cell rosettes (ER) in patients with a 
variety of primary and secondary immunodeficiency diseases, but not in most 
normal individuals (9- 11). Thymosin is believed to act by inducing maturation of 
undifferentiated lymphocytes predetermined to follow the T-cell pathway (12). 
The Wara- Ammann ER assay (13) measures the in virro response of ER in the 
presence or absence of thymosin. Patients whose ER are increased following 
incubation with thymosin appear to have a greater than normal number of precur- 
sor T cells and a thymosin-dependent immunodeficiency disorder. Failure to in- 
crease ER with thymosin may indicate that there is an adequate endogenous level 
of thymosin or a thymosin-independent disorder. 
Determination of ER formed under conditions where the sheep red blood cell 
(SRBC) lymphocyte ratio exceeds 32/l may not accurately reflect cellular immune 
competency, but instead may be an indicator of the presence and distribution of 
the T cell (14). Recent studies indicate that enumeration of ER in a system de- 
signed to measure the percentage of “avid” rosettes provides a more sensitive 
index for the determination of an altered cellular immune state (7, 15). The “avid” 
rosette test utilizes a SRBC/lymphocyte ratio of 8/l which identifies T cells that 
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demonstrate an avidity for SRBC. This avidity may be related to the density of 
SRBC receptors on the surface of T cells and/or the affinity of these receptor sites 
for SRBC (1.5). In addition, the “avid” rosette may be comparable to the “active” 
rosette previously described (16). The “active” ER test also utilizes a SRBCi 
lymphocyte ratio of 811, but unlike the “avid” ER assay, includes fetal calf serum 
in the media. In addition, the ER count is initiated approximately 5 min following 
addition of the SRBC to the lymphocyte suspension. while in the “avid” ER test. 
the SRBCilymphocyte suspension is incubated overnight at 4°C. Chisholm and 
Tubergen ( 15) have suggested that the SRBCilymphocyte ratio is the critical factor 
in the formation of ER rather than the time duration or temperature of incubation. 
Accordingly. avid ER and B lymphocytes were enumerated in patients with al- 
coholic liver disease; the effect of preincubation with thymosin on avid ER forma- 
tion was also evaluated in such patients and controls. Our results show that 
thymosin increased avid ER in patients with alcoholic hepatitis (AH) but not in 
patients with compensated alcoholic cirrhosis (CAC) or in age-equivalent con- 
trols. This suggests that there is a thymosin-dependent immunodeficiency state in 
AH which appears to be reversible with resolution of the acute episode. 
MATERIALS AND METHODS 
Srudy groz4ps. Thirty male patients with alcoholic liver disease were studied. 
Twelve patients were considered to have AH based on clinical and laboratory 
findings which included the following criteria determined after at least 5 days in 
the hospital: A recent history of alcohol consumption in excess of 1 pint of whis- 
key per day or its alcoholic equivalent: hepatomegaly on physical examination 
and/or liver scan, a total bilirubin greater than 4 mg%; and abnormalities in at least 
two of the following: (a) serum glutamic oxaloacetic transaminase (SGOT) more 
than 80 IU/ml (normal range 5-15 IU), (b) a serum albumin of less than 3 g%, or 
(c) a prothrombin time more than 2 set over the control value (Table 1). Coagula- 
tion deficiences and/or the presence of marked ascites precluded liver biopsy in all 
but five of the patients studied. In all cases where biopsy was possible, the clinical 
diagnosis of AH was confirmed by the presence of alcoholic hyalin, liver cell 
necrosis, polymorphonuclear neutrophil leukocyte (PMN) infiltration. Four of the 
five biopsies revealed concomitant micronodular cirrhosis. These criteria for the 
diagnosis of AH are similar to those used in a previous study of corticosteroid 
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evidence of a bacterial or fungal infection, acute renal impairment, or significant 
upper gastrointestinal bleeding at the time of evaluation. 
Eighteen alcoholic patients were diagnosed as having CAC on the basis of 
biopsy-proved micronodular cirrhosis without superimposed hepatitis, with 
known previous heavy alcohol intake and demonstrated clinical and laboratory 
findings compatible with quiescent disease (‘Table 1). 
Control subjects consisted of 30 healthy volunteers not known to have liver 
disease. In addition, none manifested evidence of an acute illness. Controls or 
patients with malignancy, with a history of recent viral upper respiratory illness, 
or recipients of blood transfusions within 4 weeks of the examination were 
excluded. No patients were receiving steroids or other immunosupressive 
therapy. 
Two methods of evaluation were used. The first compared the study group(s) 
with age-equivalent controls and the second compared the study group(s) with a 
larger, total control group. 
Separation of peripheral lymphocytes. Venous blood was drawn into a SO-ml 
syringe containing 50 units/ml of preservative-free heparin. The blood was diluted 
l/l in calcium- and magnesium-free Hanks’ balanced salt solution (HBSS) to 
which 0.35 g of sodium bicarbonate was added for each liter of solution. The 
diluted blood was layered in lo-ml aliquots onto 3 ml of Ficoll-Hypaque discon- 
tinuous gradient and spun at 400g for 30 min at 20°C. The cells at the interface 
were removed, washed three times in HBSS, and adjusted to a final concentration 
of 5 x 10” cells/ml. A Wright’s stain smear revealed 90-95% lymphocytes with the 
remaining cells identified as monocytes. No attempt was made to remove the 
latter cells. 
ER and thymosin treatment. Purified bovine thymosin fraction 5 (clinical qual- 
ity) was prepared (18) in concentrations of 400, 200, and 100 pg/ml in 0.9 N NaCl. 
Thymosin fraction 5 effect was determined as outlined by Wara and Ammann ( 13) 
with the single alteration that the response in the number of avid ER, rather than 
total ER, was determined. Briefly, 0.1 ml of the lymphocyte suspension was 
added to 0.1 ml of HBSS and in other tubes, to 0.1 ml of the three concentrations 
of thymosin fraction 5. Triplicate samples were prepared. The cell suspensions 
were incubated at 37°C for 10 min. SRBC from the same animal were preserved in 
Alsever’s solution and were always less than 3 weeks old. The SRBC were 
washed three times in HBSS and resuspended at 2 x 10’ cells/ml. SRBC suspen- 
sion, 0.2 ml, was added to each of the tubes with a final SRBG’lymphocyte ratio 
of 811. The tubes were capped and centrifuged for 5 min at 1808 and allowed to sit 
overnight (18-24 hr) at 4°C. The cell pellet was then resuspended by gently 
rotating at 180 rpm on a platform for 4 min. Lymphocytes binding more than three 
red cells were scored as avid T cells (7). The total ER count was obtained by 
incubating the lymphocytes at a saturated SRBC/lymphocyte ratio of 60/l, in the 
absence of thymosin. All tubes were counted in blind fashion with respect to 
patient source and knowledge of the presence of thymosin fraction 5 or the 
control situation. The mean percentage of ER-forming cells and the SEM were 
determined in the control and patient samples at that concentration of thymosin 
which produced the highest ER formation. Student’s independent t test was used to 
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compare study groups. Student’s dependent z test was used to compare ER in the 
presence or absence of thymosin within the same study groups. 
B-iymphocytr assq. The B-lymphocyte count was determined by the percent- 
age of lymphocytes staining with fluoresceinated goat antiserum to human im- 
munoglobulin (Ig). Briefly, 0.1 ml of the lymphocyte suspension was incubated 
with 0.02 ml of an Ii8 dilution of polyvalent goat antiserum against human im- 
munoglobulin in Verona1 buffer solution (VBS) supplemented with 10% fetal calf 
serum for 20 min at 37°C. The cells were washed twice with VBS and the per- 
centage of cells with membrane-bound immunoglobulin counted using a Zeiss 
fluorescent microscope. 
Recently, concern has been raised that the standard fluorescein-labeled anti- 
human Ig used in a number of investigations resulted in an over estimation of the 
number of B cells ( 19). It has been shown that rabbit anti-human Ig may reaggre- 
gate after ultracentrifugation, or form immune complexes and then attach to the 
Fc receptors of non-B lymphocytes. Thus, it was suggested that F(ab’), fragments 
of rabbit anti-Ig should be used instead. However, recent reports indicate that 
whole goat anti-human Ig may be used in place of F(ab’), fragments (20). 
RESULTS 
As shown in Table 2, the total white blood cell (WBC) as well as the PMN 
counts were significantly higher in patients with AH than in the controls. No 
differences were noted between patients with CAC and controls. The proportion 
and absolute lymphocyte counts were significantly lower in AH than in the con- 
trols, while no such differences were noted between patients with CAC and the 
controls. 
Avid ER 
There was a highly significant decrease in both the proportion and absolute 
number of avid ER in patients with AH (P < 0.001). In contrast, the proportion and 
number of avid ER were similar for patients with CAC and the controls (Table 3). 
B Lymphocytes 
There were no differences in the proportion of B cells in any of the groups. The 
absolute number of B cells was diminished in AH and probably was a reflection of 
the decreased peripheral lymphocyte count in AH (Table 3). The proportions of B 
cells obtained in the patient and control groups is higher than the currently accepted 
figures of 4- 10%. This discrepancy is probably attributable to the inclusion in our 
count of monocytes with attached cytophilic IgG antibody (20). 
Thymosin Effect 
Addition of thymosin to lymphocytes prior to incubation with SRBC resulted in 
significant increases in avid ER in patients with AH (Table 4). No significant 
changes were noted in patients with CAC or in any of the control groups. 
DISCUSSION 
A number of studies have reported diminished peripheral blood T lymphocytes 
in alcoholic liver disease in systems designed to enumerate “total” T cells (l-6). 
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TABLE 4 
EFFECT OF THYMOSIN ON AVID ER” 
Group 
Baseline avid Avid T-cell rosettes 
T-cell rosettes after thymosin 
Mean Mean 












16.0 2 1.1” 280 r 40” 20.7 f  1.2’ 365 k 52” 
25.7 -+ 1.8 682 5 94 27.6 k 1.8 712 i 85 
24.5 2 1.1 588 f  81 25.4 +- 1.0 608 c 79 
25.3 c 1.2 652 + 69 26.5 + 1.3 672 5 64 
25.5 + 0.9 593 + 46 26.2 2 1.0 604 k 45 
U Mean -t SEM. 
’ P < 0.001, equivalent and total control. 
c P i 0.001. AH baseline, Student’s paired r test. 
“P < 0.005, AH baseline, Student’s paired I test. 
count of “total” T cells than the controls while a similar evaluation of patients 
with CAC did not reveal significant differences. 
The observation of normal avid ER and total T-cell counts in CAC is supported 
by the work of some investigators (5) and is in disagreement with others (2-4). 
These conflicting results may represent differences in patient selection as well as 
criteria for exclusion from the study. As an example, the requirement that subjects 
TABLE 5 
“TOTAL” T-CELL ROSETTES” 
Group Percentage ER Mean No./mm” 
Alcoholic 





cirrhosis ( 18) 
Equivalent 
control (18) 
Total controls (30) 
53.3 + 1.7h 985 2 111’ 
61.3 e 1.8 1635 k 212 
60.6 r 1.2 1384 + 190 
62.4 c 1.3 1625 + 165 
61.0 + 1.1 1437 + 115 
0 Means + SEM. 
h P < 0.005, equivalent control; P < 0.001, total controls. 
c P < 0.05. equivalent and total controls. 
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not have a recent upper respiratory illness is predicated on the reported inhibiting 
effect that the influenza virus has on ER formation (2 I). Thus, a history of recent 
upper respiratory illnesses in patients and controls was cause for exclusion from 
the study. 
There are a number of possibilities which may account for the decrease in 
peripheral T cells in AH. Sensitized lymphocytes may migrate to the liver deplet- 
ing the peripheral blood of mature T cells (4). T cells may be sequestered in the 
liver or subjected to the toxic effect of alcohol which could affect cellular function 
or kinetics (2). In addition, alcoholic hyalin appears to induce complex formation 
by combining with antibody and is carried as complexes on lymphocytes (22). It is 
possible such complexes may adhere to the surface of T lymphocytes and prevent 
rosette formation. A similar mechanism has been suggested to account for the 
decreased proportion of rosettes seen in systemic lupus erythematosis ( I1 ). 
A serum factor designated as a rosette-inhibiting factor (RIF) has been de- 
scribed in patients with acute and chronic viral hepatitis (23). RIF has been 
characterized as an immunoregulatory plasma lipoprotein that can suppress 
rosette formation of normal T lymphocytes in lritr'o. Lymphocytes affected by RIF 
can regenerate normal rosette formation when cultured in the presence of normal 
serum. 
Of import to the present study is the observation that RIF inhibits the rosette 
function of only a subpopulation of T lymphocytes (24). No greater than a 40- 50% 
relative inhibition of rosette function was observed even with a IOOO-fold excess of 
RIF. The number of “active” rosettes is normal however in patients who are RIF 
(+). while the total number of rosettes is reduced (25). Although a RIF-like factor 
has not been described in the sera of patients with alcoholic liver disease. its 
presence would not appear to alter avid rosette counts as this assay appears to 
identify a subgroup of lymphocytes similar to that of the “active” rosette assay 
(15). 
Alterations in cell-mediated immunity have been reported in alcoholic liver 
disease. Patients with alcoholic cirrhosis show a decreased ability to be sensitized 
to dinitrochlorobenzene (1). Production of migration-inhibition factor and ti- 
brogenic factor was increased in lymphocytes of patients with AH incubated with 
purified alcoholic hyalin but not in healthy controls, acute viral hepatitis, fatty 
liver or inactive cirrhosis (26, 27). Lymphocytes from patients with AH were 
found to be cytotoxic to Chang cells (22). autologous liver cells (22), and rabbit 
hepatocytes (28). 
It has been suggested that there is a reversible depression of the cell-mediated 
immune system in patients with AH, as manifested by cutaneous delayed hyper- 
sensitivity and T-cell proportions (5). With recovery from AH, even in the pres- 
ence of cirrhosis, the T-cell proportions return to the normal range and skin tests 
for common antigens reveal greater “positivity” when expressed in millimeters of 
induration (5). 
The uniform increase in avid ER in AH after incubation with thymosin (Fig. I) 
suggests that there is a subset of lymphocytes that may be considered precursors 
to cells capable of forming spontaneous rosettes with SRBC. It is believed that 
immature T lymphocytes may constitute a subset of null cells (10). Recent studies 
have shown that thymosin induces null cells to form ER in patients with T-cell 
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FIG. 1. In virro effect of thymosin on peripheral avid T rosettes in alcoholic liver disease. 
defects (29). Moreover, thymosin acts on human null cells possessing 
T-lymphocyte antigens, but not B-cell antigens (30). 
The actual percentage increase in avid ER in AH was small. Thus, while the 
baseline avid ER in AH was 63% of the control value, thymosin treatment resulted 
in avid ER attaining 81% of the baseline values for the controls. This may indicate 
that only a small proportion of lymphocytes induced to maturity by thymosin 
possess the capability for forming avid ER. It has been shown that the functional 
change induced by thymosin may not be correlated to total ER formation, but 
rather, to increased active ER formation (29). No attempt was made to charac- 
terize the response of lymphocytes to thymosin in a saturated SRBClymphocyte 
milieu. 
The thymus has been shown to exert an endocrine influence on the maturation 
and function of the immune system. This has been demonstrated previously in a 
variety of animal and human models by use of thymus gland transplantation and 
by the administration of thymic extracts (31-33). Thymosin appears to hasten 
maturation of immature T cells with induction of surface markers found in mature 
cells (9). The short period of incubation required to induce the appearance of 
T-lymphocyte surface markers points to a membrane effect rather than activation 
of nuclear or cytoplasmic mechanisms. 
Thymosin increases intracellular levels of cyclic GMP, but not cyclic AMP in 
murine thymocytes. This finding suggests that a mechanism of action for thymosin 
may involve modulation of cyclic GMP levels in lymphocytes (34). 
It would be premature to ascribe the decreased number of avid ER in AH to 
dysfunction of the thymic gland, or to alterations in the effective serum thymic 
factor concentration. It does appear, however, that the target immature T cell 
retains the capacity to respond to thymic factors. 
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